Prognostic Implications of Primary Site in Cutaneous Head and Neck Melanoma After the Implementation of Sentinel Node Biopsy: A SEER-Based Analysis (2011-2020).

Simatul Rashid, Catherine Yu, Nicholas Gulati, Parul Agarwal, Maaike van Gerwen

Abstract read

In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Simatul Rashid *Renaissance School of Medicine at Stony Brook University, Long Island, NY, USA. simatulrashid@gmail.com.

Catherine Yu *Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Nicholas GulatiDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Parul AgarwalTisch Cancer Institute, Department of Population Health Science and Policy and Institute for Healthcare Delivery Science, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Maaike van GerwenDepartment of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Funding

Division of Cancer Prevention, National Cancer Institute R25CA281789

6 · The paper itself

Abstract

backgroundScalp and neck (SN) melanoma demonstrates the worst prognosis among all cutaneous head and neck melanomas (CHNMs). The objective of this study was to evaluate the melanoma-specific survival (MSS) in SN melanoma compared with other CHNM after the widespread clinical adaptation of sentinel lymph node biopsy in 2011 and asses whether tumor site is associated with distant metastases. PATIENTS AND

methodsA retrospective cohort study was carried out using Surveillance, Epidemiology, and End Result (SEER) data from 2011 to 2020, comprising 13,825 CHNM cases. Cox and multinomial logistic regression models were used to estimate adjusted hazard ratios and adjusted odds ratio (aORs).

resultsSN melanoma was associated with significantly worse MSS, with 5-year MSS rates of 76.5% versus 82.7%. Multivariable analysis showed SN melanoma had worse MSS (aHR 1.28; 95% confidence interval [CI] 1.16-1.41) and higher odds of presenting with lung metastases (aOR 2.39; 95% CI 1.35-4.25) and multisite metastases (aOR 2.23; 95% CI 1.28-3.88). A limitation of the study was that the SEER database groups SN together despite previous research suggesting that the scalp component contributes to most of the poor prognoses.

conclusionsSN melanoma is associated with worse MSS among all CHNMs despite the routine use of SLNB. SN melanoma also follows a distinct metastatic pattern to solid organs, particularly to the lungs.

Indexed as

Head and Neck NeoplasmsMelanomaSentinel Lymph Node BiopsySkin NeoplasmsAdultAgedCutaneous Malignant MelanomaFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRetrospective StudiesSEER ProgramSurvival RateCutaneous head and neck melanomaHead and neck melanomaMelanoma metastasesMelanoma-specific survivalScalp and neck melanomaScalp melanomaSEER databaseSentinel lymph node biopsy

Identifiers

PMID41803580

DOI10.1155/2012/647684

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.